A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca2+ homeostasis in 3xTg-AD mice.

Neuropharmacology
Tian LiJin-Shun Qi

Abstract

Alzheimer's disease (AD) is a progressively neurodegenerative disorder, which seriously affects human health and cannot be stopped by current treatments. Type 2 diabetes mellitus (T2DM) is a risk factor for AD. Our recent studies reported the neuroprotective effects of a GLP-1/GIP/Glucagon receptor triagonist (Triagonist), a novel unimolecular anti-diabetic drug, in cognitive and pathological improvements of 3xTg-AD mice. However, the detailed electrophysiological and molecular mechanisms underlying neuroprotection remain unexplored. The present study investigated the underlying electrophysiological and molecular mechanisms further by using whole-cell patch clamp techniques. Our results revealed that chronic Triagonist treatment effectively reduced working memory and reference memory errors of 3xTg-AD mice in a radial maze test. In addition, the Triagonist increased spontaneous excitatory synaptic activities, differentially modulated voltage- and chemically-gated Ca2+ flux, and reduced the over-excitation of pyramidal neurons in hippocampal slices of 3xTg-AD mice. In addition, chronic Triagonist treatment also up-regulated the expression levels of synaptophysin and PSD-95 in the hippocampus of 3xTg-AD mice. These results indica...Continue Reading

References

Jul 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·N M Hoosein, R S Gurd
Jan 1, 1994·Peptides·A M Kaplan, S R Vigna
Jan 1, 1994·Annual Review of Neuroscience·M Hollmann, S Heinemann
Jan 7, 1993·Nature·T V Bliss, G L Collingridge
Dec 1, 1996·Journal of Neurocytology·M E CalhounP R Mouton
Apr 17, 2002·Cell·Alaa El-Din El-HusseiniDavid S Bredt
Sep 17, 2002·The American Journal of Cardiology·Barry J Goldstein
Mar 5, 2003·Pharmacological Reviews·Kelly E MayoDaniel J Drucker
Jan 22, 2004·Nature Reviews. Neuroscience·Gina G Turrigiano, Sacha B Nelson
Apr 28, 2004·Free Radical Biology & Medicine·Xavier GironèsFélix F Cruz-Sánchez
Feb 18, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jenny NybergPeter S Eriksson
Feb 22, 2005·The Journal of Biological Chemistry·Angelo DemuroCharles G Glabe
Jul 19, 2005·Nature Neuroscience·Eric M SnyderPaul Greengard
Jul 11, 2006·The Journal of Clinical Investigation·Steven E ShoelsonAllison B Goldfine
Oct 6, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Kim A CeloneReisa A Sperling
Oct 5, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Yasushi SatohKunio Takishima
Aug 5, 2008·Trends in Neurosciences·Ilya Bezprozvanny, Mark P Mattson
Mar 23, 2010·Cell·Christopher K GlassFred H Gage
Oct 28, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Xindao HuErik W Dent
Dec 2, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Deepti PutchaReisa Sperling

❮ Previous
Next ❯

Citations

Mar 17, 2020·Expert Opinion on Investigational Drugs·Christian Hölscher
Jul 3, 2021·Expert Opinion on Investigational Drugs·Jonathan FlintoffThomas Hj Burne
Oct 23, 2021·The European Journal of Neuroscience·Xiao-Yu LiuPing Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Alzheimer's Disease: Animal Models

Alzheimer's disease is a neurodegenerative disease which can be studied using various experimental systems. This feed focuses on animal models used for Alzheimer's disease research.